The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Knee Osteoarthritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market.
Some of the key takeaways from the Knee Osteoarthritis Pipeline Report:
Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years.
Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc, Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, Bioventus LLC, Genascence Corporation, Immunis, Inc., Novartis, Techfields Pharma Co. Ltd, Eli Lilly and Company, and others, are developing therapies for the Knee Osteoarthritis treatment
Emerging Knee Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, PTP-001, GNSC-001, IMM01-STEM, RHH646, X0002, Retatrutide, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.
In August 2023, “Exceptional results from our Phase 2b clinical trial of EP-104IAR for pain associated with knee osteoarthritis were announced during Eupraxia Pharmaceuticals Inc. second quarter,” said Dr. James Helliwell, CEO of Eupraxia. The EP-104IAR Phase 2b research is the largest in the organization’s history, and Eupraxia Pharmaceuticals thinks the results are a key barometer for the medication candidate and our underlying diffusion technology. Eupraxia Pharmaceuticals is collaborating with key opinion leaders to determine the best course of action for EP-104IAR based on the trial’s results and getting ready for an FDA End of Phase 2 meeting.
In December 2022, For its knee OA treatment candidate, lorecivivint (“LOR”), Biosplice Therapeutics, Inc. recently released possible structure-modifying highlights from the ongoing long-term extension study, OA-07. The study’s findings support the idea that frequent injections of lorecivivint may be effective in preventing structural progression and improving symptoms.
In August 2020, A long-term extension study was started by Biosplice Therapeutics to assess the effectiveness and safety of Lorecivivint in people with knee osteoarthritis. A long-term extension to the Phase III parent-study SM04690-OA-11 is intended by this study.
Knee Osteoarthritis Overview
The most typical type of arthritis is osteoarthritis (OA). Some people refer to it as “wear and tear” arthritis or degenerative joint disease. It usually affects the hands, hips, and knees. A joint’s cartilage starts to degrade and the underlying bone starts to change as a result of OA.
Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment-
Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include:
M6495: Merck KGaA
PPV 06: Peptinov
LG00034053: LG Chem
StroMel: Akan Bioscience
EP-104IAR: Eupraxia Pharmaceuticals Inc.
OLP 1002: OliPass Corporation
JTA-004: Bone Therapeutics
X 0002: Techfields Pharma
Lorecivivint: Biosplice Therapeutics
PTP-001: Bioventus LLC
GNSC-001: Genascence Corporation
IMM01-STEM: Immunis, Inc.
X0002: Techfields Pharma Co. Ltd
Retatrutide: Eli Lilly and Company
Knee Osteoarthritis Route of Administration
Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Knee Osteoarthritis Molecule Type
Knee Osteoarthritis Products have been categorized under various Molecule types, such as
Knee Osteoarthritis Pipeline Therapeutics Assessment
Knee Osteoarthritis Assessment by Product Type
Knee Osteoarthritis By Stage and Product Type
Knee Osteoarthritis Assessment by Route of Administration
Knee Osteoarthritis By Stage and Route of Administration
Knee Osteoarthritis Assessment by Molecule Type
Knee Osteoarthritis by Stage and Molecule Type
DelveInsight’s Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies
Some of the key companies in the Knee Osteoarthritis Therapeutics Market include:
Key companies developing therapies for Knee Osteoarthritis are – Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others.
Knee Osteoarthritis Pipeline Analysis:
The Knee Osteoarthritis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies
Knee Osteoarthritis Pipeline Market Drivers
Increase in prevalence of Osteoarthritis, robust Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market.
Knee Osteoarthritis Pipeline Market Barriers
However , the risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth.
Scope of Knee Osteoarthritis Pipeline Drug Insight
Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc, Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, Bioventus LLC, Genascence Corporation, Immunis, Inc., Novartis, Techfields Pharma Co. Ltd, Eli Lilly and Company , and others
Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, PTP-001, GNSC-001, IMM01-STEM, RHH646, X0002, Retatrutide, and others
Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers
Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials
Table of Contents
1. Knee Osteoarthritis Report Introduction
2. Knee Osteoarthritis Executive Summary
3. Knee Osteoarthritis Overview
4. Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment
5. Knee Osteoarthritis Pipeline Therapeutics
6. Knee Osteoarthritis Late Stage Products (Phase II/III)
7. Knee Osteoarthritis Mid Stage Products (Phase II)
8. Knee Osteoarthritis Early Stage Products (Phase I)
9. Knee Osteoarthritis Preclinical Stage Products
10. Knee Osteoarthritis Therapeutics Assessment
11. Knee Osteoarthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Knee Osteoarthritis Key Companies
14. Knee Osteoarthritis Key Products
15. Knee Osteoarthritis Unmet Needs
16 . Knee Osteoarthritis Market Drivers and Barriers
17. Knee Osteoarthritis Future Perspectives and Conclusion
18. Knee Osteoarthritis Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States